RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Focus Forward

Posted 01 November 2010 | By

The healthcare product industry remains one of the most closely watched and critically important in the world. Maintaining a balance between public health and private business interests for the overall public good is both challenging and vital. Consider some of the dynamics of current discussions: there is widespread concern about the cost of healthcare products even as the sector is regarded as key to economic growth; the public demands better and more-effective products but has less tolerance for risk; the review of new products must be based upon sound science and good data but scientific standards are lacking in some instances and data requirements may be unclear.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.